Clinical Trial Update: BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial update on BI 811283 in combination with cytarabine for adults with newly diagnosed acute myeloid leukemia ineligible for intensive treatment; resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• BI 811283
• CYTARABINE (CYTARABINE)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Leukemia, Myeloid, Acute | Phase 2 | Status: COMPLETED | Results posted: 2015-05-25